Literature DB >> 28240574

Elucidating the role of clofazimine for the treatment of tuberculosis.

M R O'Donnell1, N Padayatchi2, J Z Metcalfe3.   

Abstract

Clofazimine (CFZ), a riminophenazine and a key component of the treatment regimen for lepromatous leprosy, has been rehabilitated clinically for the treatment of multidrug-resistant tuberculosis (MDR-TB). Observational studies and a randomized control trial suggest efficacy in the treatment of MDR-TB and the potential for treatment shortening. Animal and translational research have shown mixed results. In this article, we review key clinical, animal, and translational data to better understand the potential role of CFZ in the treatment of MDR-TB and in shortening anti-tuberculosis treatment.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 28240574     DOI： 10.5588/ijtld.16.0073

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN： 1027-3719            Impact factor:   2.373


  6 in total

1.  Activity of Clofazimine and TBI-166 against Mycobacterium tuberculosis in Different Administration Intervals in Mouse Tuberculosis Models.

Authors:  Hui Zhu; Lei Fu; Bin Wang; Xi Chen; Jiaojie Zhao; Haihong Huang; Yu Lu
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

2.  Pharmacogenetics of Between-Individual Variability in Plasma Clearance of Bedaquiline and Clofazimine in South Africa.

Authors:  David W Haas; Mahmoud Tareq Abdelwahab; Stijn W van Beek; Paxton Baker; Gary Maartens; Yuki Bradford; Marylyn D Ritchie; Sean Wasserman; Graeme Meintjes; Karen Beeri; Neel R Gandhi; Elin M Svensson; Paolo Denti; James C M Brust
Journal:  J Infect Dis       Date:  2022-08-12       Impact factor: 7.759

3.  A new era for treatment of drug-resistant tuberculosis.

Authors:  Neel R Gandhi; James C M Brust; N Sarita Shah
Journal:  Eur Respir J       Date:  2018-10-04       Impact factor: 16.671

4.  Clofazimine for Treatment of Extensively Drug-Resistant Pulmonary Tuberculosis in China.

Authors:  Qingfeng Wang; Yu Pang; Wei Jing; Yufeng Liu; Na Wang; Hongyun Yin; Qing Zhang; Zhizhong Ye; Min Zhu; Fujian Li; Ping Liu; Tingting Wu; Wei Chen; Wei Wu; Zhihua Qin; Chao Qiu; Qunyi Deng; Tao Xu; Jing Wang; Ru Guo; Yadong Du; Jun Wang; Hairong Huang; Xiaohong Chen; Naihui Chu
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

5.  Dually Acting Nonclassical 1,4-Dihydropyridines Promote the Anti-Tuberculosis (Tb) Activities of Clofazimine.

Authors:  Fabian Lentz; Norbert Reiling; Gabriella Spengler; Annamária Kincses; Andrea Csonka; Joseph Molnár; Andreas Hilgeroth
Journal:  Molecules       Date:  2019-08-08       Impact factor: 4.411

6.  Clofazimine pharmacokinetics in patients with TB: dosing implications.

Authors:  Mahmoud Tareq Abdelwahab; Sean Wasserman; James C M Brust; Neel R Gandhi; Graeme Meintjes; Daniel Everitt; Andreas Diacon; Rodney Dawson; Lubbe Wiesner; Elin M Svensson; Gary Maartens; Paolo Denti
Journal:  J Antimicrob Chemother       Date:  2020-11-01       Impact factor: 5.790
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.